WO1997025023A1 - Skin treatment formulation and uses thereof - Google Patents
Skin treatment formulation and uses thereof Download PDFInfo
- Publication number
- WO1997025023A1 WO1997025023A1 PCT/IT1997/000002 IT9700002W WO9725023A1 WO 1997025023 A1 WO1997025023 A1 WO 1997025023A1 IT 9700002 W IT9700002 W IT 9700002W WO 9725023 A1 WO9725023 A1 WO 9725023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- hydrolysed
- preparation according
- equivalent
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a compound for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin and related tissues. More particularly, the invention relates to a product for the treatment of: 1. skin atrophy striae, 2 skin wrinkles,
- the invention also relates to the uses of the said compound.
- Background art Skin atrophy and the phenomena associated therewith are mainly due to a deficiency in the two proteins of the skin, collagen and elastin, the first being responsible for nourishing and revitalizing the skin tissues while the second has the function of making the skin tissues elastic.
- the subject of the present invention is a product for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin, based on elastin and collagen, which product makes it possible to obtain better and especially longer lasting results.
- the product of the invention contains a combination of at least the following components: 1) collagen, 2) elastin,
- a suitable vehicle which may also consist of a physiologically acceptable solution, depending on the type of administration for which the formulation is intended.
- vascularization In certain cases, a reduction in vascularization accompanies the unaesthetic skin conditions mentioned.
- administration of the optional local vasodilator together with the collagen and elastin makes it possible to re-establish peripheral blood circulation in the zone treated, thereby giving rise to localized vasodilation and thus allowing the two proteins to reach the treated zones.
- the temporary vasodilation produced by the vasodilatory substance helps vascularization in the tissues and facilitates the provision of nutrients by the blood.
- RNA helps the tissues receiving it to manufacture proteins with characteristics similar to the proteins administered, while RNA serves to create a memory, in the tissues receiving it, for the two proteins supplied in order to allow the tissues themselves to reproduce these proteins.
- RNA or DNA therefore makes it possible to accelerate the healing process by stimulating the autonomous production of collagen and elastin by the skin tissues being treated.
- the two acids are preferably used in combination, but appreciable results may also be obtained with only one of the two acids or the respective salt.
- the compound may comprise, besides the four main components referred to above, one or more secondary components chosen from one or more of the following groups: amino acids; - enzymes and coenzymes; Vitamin C keratin (restricted to treatment of the scalp) .
- useful enzymes for the use according to the invention are the following: pepsin, pyridoxine (Vitamin B6 coenzyme) , biotin or Vitamin H (Vitamin B6 coenzyme) .
- pepsin pyridoxine
- pyridoxine Vitamin B6 coenzyme
- biotin or Vitamin H Vitamin H
- the amino acids added to the formulation metabolize the proteins, that is to say they are involved in the formation of collagen and elastin.
- the enzymes and coenzymes are catalysts of the process of protein metabolism, that is to say they increase the rate of biochemical reaction of the amino acids to proteins. Their presence in combination with amino acids therefore accelerates the metabolization of protein.
- antioxidant represented by Vitamin C
- Keratin the use of which is limited to formulations for treating the scalp, constitutes specific nourishment for promoting the regrowth and strengthening of the hair.
- composition of the product varies depending on the mode of administration, in particular as regards the vehicles and the excipients.
- the four fundamental components or five in the case of the use of both DNA and RNA
- they may be used in the following amounts, expressed in parts by weight, including in the absence of other components: Hydrolysed collagen: 3-10 parts
- RNA Sodium ribonucleate (RNA) 3-10 parts Excipients and vehicles qs
- the sodium deoxyribonucleate and ribonucleate can be used independently of or in combination with each other.
- compositions varying within the following ranges, again expressed in parts by weight:
- RNA Sodium ribonucleate 4-8 parts in the presence of appropriate vehicles and/or excipients.
- appropriate vehicles and/or excipients for administration by subcutaneous or intradermal injection or infiltration, the components mentioned above are prepared in a physiological solution, which in this case represents the vehicle. Typically, the parts by weight shown above are combined with 1000 parts by weight of physiological solution.
- Appropriate excipients and vehicles are used for topical administration, and a few examples of these will be given in the following text together with respective amounts, with respect to a few particularly effective formulations.
- secondary components such as certain enzymes and amino acids.
- a formulation to which all the secondary components mentioned above have been added is given below.
- the composition relates to an amount of 10 ml, equivalent to 10 g in physiological solution:
- Vitamin C 350-650 mg Hydrolysed keratin (*) 20-40 mg
- compositions given above remain valid for topical application as regards the first fifteen components, except that they would be in a different and— higher concentration, in view of the increased difficulty of absorption and the increased dispersion. Moreover, the physiological solution would be replaced by a combination of various vehicles and excipients.
- compositions may be used, relative to 10 g of product (where the preferred amounts, again in mg, are shown in parentheses) :
- Hydrolysed collagen 65-200 mg 90-170
- Procaine hydrochloride 20-60 mg (30-50)
- Vehicle hydrogenated polyoxyethylenated castor oil 100-300 mg (150-230)
- ampules for topical use in the treatment of atrophy in which case the excipient is replaced by water, with the addition of preserving agents.
- Ampules for the treatment of the scalp may have the same composition as ampules for the treatment of atrophy, with the addition of keratin in an amount of from 60 to 120 mg per 10 g of product.
- the DNA and the RNA may also be used in the form of potassium deoxyribonucleate and potassium ribonucleate or in another compatible form.
- the application methods vary depending on the type of treatment and on the route of administration. The latter may be carried out topically or by infiltration via subcutaneous, intra- or mesodermal injection of the compound into the site of the atrophies.
- the number of applications and the amount of product applied vary according to the area of tissue to be treated and its condition. A few general indications are given below, which a person skilled in the art will use as a guideline for selecting the most suitable mode of application in each individual case.
- Treatment of cutaneous striae subcutaneous infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the stria along its entire length.
- a tunnel is formed which is filled with the solution as the needle is withdrawn.
- intradermal infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the wrinkle along its entire length.
- a tunnel is formed- which is filled with the solution as the needle is withdrawn.
- mesodermal infiltrations that is to say infiltrations into the dermis but to a deeper level than intradermal infiltrations
- a syringe with a microneedle in order to provide deep and diffuse nourishment for the tissues concerned.
- Treatment of the scalp and of alopecia intradermal infiltrations into the scalp (trichomesotherapy) are performed using a syringe with a microneedle.
- Treatment of skin chapping intradermal infiltrations are performed into the area concerned using a syringe with a microneedle. 6. Treatment of slow cicatrization: intradermal infiltrations are performed into the area concerned using a syringe with a microneedle.
- the number of applications depends on the seriousness of the condition of the tissue treated. In general, the number of applications may range from 5 to 50.
- the amount of solution administered varies according to the size of the area under treatment. Generally speaking, about 0.1 ml of product per cm 2 of tissue treated may be applied in the treatment of cutaneous striae.
- Cosmetic treatment by means of topical application of the compound is carried out by rubbing the ampule preparation onto the area to be treated or by massaging into the area concerned in the case of cream preparations.
- Topical use involves application twice daily over a period varying between one and six months, depending on the seriousness of the condition of the skin tissue.
- NaCI queous solution (0.9%): stabilized pig-collagen 30 g/l sterilized pig-elastin 10/15 g/l glycine 2/4 g/l proline 6/10 g/l hydroxyproline 2/4 g/l
- Collagen and elastin may be of animal or vegetal origin.
- a process for obtaining hydrolysed cross ⁇ linked collagen and hydrolysed cross-linked elastin is described hereinbelow:
- A.stabilised pig-collagen is mixed in a vacutainer under nitrogen atmosphere at 35/38° for 90 min.; B.the product is filtered on a 1-micrometre filter;
- steps C, D and E are repeated;
- gelatine On the bottom of the container a translucent homogeneous gelatine is collected.
- the gelatine may be brought at the desired viscosity by addition of a sterilized 0.9% acqueous solution of NaCI.
- Hydrolized aminoacids, hydrolized DNA and RNA and hydrolized biotin as well as procaine hydrocloride are added to the proteins treated as above described in order to obtain the above preparation.
- the same process can be used with twice the amount of elastin and collagen (i.e. 60 g/l collagen and 20/30 g/l elastin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13185/97A AU709842B2 (en) | 1996-01-10 | 1997-01-08 | Skin treatment formulation and uses thereof |
EP97900732A EP0873113A1 (en) | 1996-01-10 | 1997-01-08 | Skin treatment formulation and uses thereof |
BR9706943A BR9706943A (en) | 1996-01-10 | 1997-01-08 | Skin treatment formulation and its uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96FI000002A IT1289845B1 (en) | 1996-01-10 | 1996-01-10 | FORMULA FOR THE TREATMENT OF SKIN AND ITS USES |
ITFI96A000002 | 1996-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997025023A1 true WO1997025023A1 (en) | 1997-07-17 |
Family
ID=11351445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT1997/000002 WO1997025023A1 (en) | 1996-01-10 | 1997-01-08 | Skin treatment formulation and uses thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0873113A1 (en) |
AU (1) | AU709842B2 (en) |
BR (1) | BR9706943A (en) |
CA (1) | CA2242636A1 (en) |
IT (1) | IT1289845B1 (en) |
WO (1) | WO1997025023A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031337A1 (en) * | 1997-01-21 | 1998-07-23 | Thorel Jean Noel | Cosmetic or dermo-phamaceutical products compatible with cutaneous ecology |
WO2003045340A1 (en) * | 2001-11-27 | 2003-06-05 | Unilever Plc | Hair treatment compositions |
WO2003082230A2 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Topical use of vitamin b6 compositions |
ITRM20090124A1 (en) * | 2009-03-23 | 2010-09-23 | Marco Nicoletti | COSMETIC COMPOSITION CONTAINING COLLAGEN AND ELASTIN |
WO2012101473A1 (en) * | 2011-01-27 | 2012-08-02 | Abdula Kurkayev | Nanocomposite formulations and method of skin care treatment for rejuvanation and correction of skin defects |
JP2013221005A (en) * | 2012-04-16 | 2013-10-28 | Katsumi Yamaguchi | Skin quality improving composition and method for producing the same |
US11260018B2 (en) | 2015-09-17 | 2022-03-01 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration and moisturization |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE726015A (en) * | 1966-06-20 | 1969-05-29 | ||
FR2592790A1 (en) * | 1986-01-16 | 1987-07-17 | Villano Guy | Cosmetic preparation having a regenerative and anti-wrinkle action |
FR2609393A1 (en) * | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
EP0283893A1 (en) * | 1987-03-23 | 1988-09-28 | R.P. DENIS S.p.A. | Novel cosmetic formulations |
EP0471135A2 (en) * | 1990-08-14 | 1992-02-19 | Kenneth M. Hallam | Compositions, medicaments and methods for the promotion of hair growth |
JPH06128138A (en) * | 1992-10-15 | 1994-05-10 | Kyowa Hakko Kogyo Co Ltd | Cosmetic |
-
1996
- 1996-01-10 IT IT96FI000002A patent/IT1289845B1/en active IP Right Grant
-
1997
- 1997-01-08 EP EP97900732A patent/EP0873113A1/en not_active Withdrawn
- 1997-01-08 BR BR9706943A patent/BR9706943A/en unknown
- 1997-01-08 AU AU13185/97A patent/AU709842B2/en not_active Ceased
- 1997-01-08 WO PCT/IT1997/000002 patent/WO1997025023A1/en not_active Application Discontinuation
- 1997-01-08 CA CA002242636A patent/CA2242636A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE726015A (en) * | 1966-06-20 | 1969-05-29 | ||
FR2592790A1 (en) * | 1986-01-16 | 1987-07-17 | Villano Guy | Cosmetic preparation having a regenerative and anti-wrinkle action |
EP0283893A1 (en) * | 1987-03-23 | 1988-09-28 | R.P. DENIS S.p.A. | Novel cosmetic formulations |
FR2609393A1 (en) * | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
EP0471135A2 (en) * | 1990-08-14 | 1992-02-19 | Kenneth M. Hallam | Compositions, medicaments and methods for the promotion of hair growth |
JPH06128138A (en) * | 1992-10-15 | 1994-05-10 | Kyowa Hakko Kogyo Co Ltd | Cosmetic |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 121, no. 8, 22 August 1994, Columbus, Ohio, US; abstract no. 91353, SUZUKI, TADASHI ET AL: "cosmetics for rough skin" XP002030251 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031337A1 (en) * | 1997-01-21 | 1998-07-23 | Thorel Jean Noel | Cosmetic or dermo-phamaceutical products compatible with cutaneous ecology |
US6342236B1 (en) | 1997-01-21 | 2002-01-29 | THOREL JEAN-NOëL | Cosmetic products compatible with cutaneous ecology |
WO2003045340A1 (en) * | 2001-11-27 | 2003-06-05 | Unilever Plc | Hair treatment compositions |
WO2003082230A2 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Topical use of vitamin b6 compositions |
WO2003082230A3 (en) * | 2002-03-28 | 2003-11-27 | Procter & Gamble | Topical use of vitamin b6 compositions |
US7235249B2 (en) | 2002-03-28 | 2007-06-26 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
ITRM20090124A1 (en) * | 2009-03-23 | 2010-09-23 | Marco Nicoletti | COSMETIC COMPOSITION CONTAINING COLLAGEN AND ELASTIN |
WO2012101473A1 (en) * | 2011-01-27 | 2012-08-02 | Abdula Kurkayev | Nanocomposite formulations and method of skin care treatment for rejuvanation and correction of skin defects |
JP2013221005A (en) * | 2012-04-16 | 2013-10-28 | Katsumi Yamaguchi | Skin quality improving composition and method for producing the same |
US11260018B2 (en) | 2015-09-17 | 2022-03-01 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration and moisturization |
Also Published As
Publication number | Publication date |
---|---|
ITFI960002A1 (en) | 1997-07-10 |
CA2242636A1 (en) | 1997-07-17 |
ITFI960002A0 (en) | 1996-01-10 |
AU1318597A (en) | 1997-08-01 |
IT1289845B1 (en) | 1998-10-16 |
BR9706943A (en) | 1999-04-06 |
AU709842B2 (en) | 1999-09-09 |
EP0873113A1 (en) | 1998-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6270811B1 (en) | Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid | |
US4810693A (en) | Method for inducing biological coverings in wounds | |
US8603973B2 (en) | Skincare composition comprising HSA fusion protein, preparation method and uses thereof | |
AU2005205917B2 (en) | Use of low-dose erythropoietin for stimulation of endothelial progenitor cells, for organ regeneration and for slowing the progression of end-organ damage | |
KR20120089433A (en) | Injectable composition combining a filling agent and a fibroblast growth medium | |
CA2042014A1 (en) | Method of treating or preventing baldness with compositions containing fibroblast growth factor | |
CN101453985A (en) | Compositions for promoting hair growth | |
JPS63185918A (en) | Cosmetic composition | |
CN1160582A (en) | External-use composite containing cell growth factor | |
JP3321712B2 (en) | Topical hair restorer containing pine extract | |
US6858201B2 (en) | Methods for treating fingernails and toenails | |
AU709842B2 (en) | Skin treatment formulation and uses thereof | |
RU2202362C2 (en) | Composition for topical usage containing human epidermis factor growth | |
US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
US20200164037A1 (en) | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth | |
GB2210789A (en) | Topical application for skin care | |
CN101596310A (en) | A kind of artificial substrate membrane emulsifying paste that is used for wound repair | |
JP5010913B2 (en) | Tissue regeneration preparation containing atrial diuretic hormone family molecule as active substance, tissue regeneration method using the preparation, hair growth, hair growth, hair restorer and skin tissue repair improving agent containing atrial diuretic hormone family molecule as active substance Hair growth, hair thickening, hair growth promoting method and skin tissue repair improving method using the preparation | |
JPH08319219A (en) | Composition for promoting to prevent root base from falling out and/or to regenerate it | |
JPS617209A (en) | Hair tonic composition | |
RU2292906C2 (en) | Pharmaceutical and cosmetic compositions containing placental growth factor plgf-1 | |
JP2002284668A (en) | Preventive and therapeutic agent against darkening | |
US20050276766A1 (en) | Methods and compositions for increasing skin remodeling | |
CN110063936A (en) | A kind of recombination human acidic mechanocyte growth factor liquid preparation | |
RU2144815C1 (en) | Method of production of regenerating cosmetic cream for skin care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2242636 Country of ref document: CA Ref country code: CA Ref document number: 2242636 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997900732 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997900732 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97525062 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997900732 Country of ref document: EP |